Mollie Leoni Sells 4,963 Shares of Kura Oncology, Inc. (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURAGet Free Report) insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kura Oncology Trading Down 1.8 %

Shares of Kura Oncology stock opened at $7.77 on Wednesday. Kura Oncology, Inc. has a 52-week low of $6.98 and a 52-week high of $24.17. The firm has a market capitalization of $604.20 million, a PE ratio of -3.29 and a beta of 0.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company’s fifty day moving average price is $9.23 and its two-hundred day moving average price is $15.69.

Kura Oncology (NASDAQ:KURAGet Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. On average, analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Scotiabank dropped their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. JMP Securities reissued a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Tuesday, November 19th. Jefferies Financial Group dropped their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. Finally, UBS Group began coverage on shares of Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $27.38.

View Our Latest Report on Kura Oncology

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently modified their holdings of the stock. Hsbc Holdings PLC lifted its position in shares of Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after buying an additional 2,167 shares during the period. Marshall Wace LLP bought a new position in shares of Kura Oncology during the second quarter valued at $541,000. AQR Capital Management LLC lifted its holdings in shares of Kura Oncology by 251.5% during the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after acquiring an additional 58,422 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after purchasing an additional 1,976 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of Kura Oncology in the 2nd quarter worth about $196,000.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Featured Articles

Insider Buying and Selling by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.